Pediatrik Nöroloji Hastalarinda İlaç Döküntüleri (Erüpsiyonlari)
Özet
Çocuklarda antiepileptik ilaç kullanımı, tanı ve yönetimi zor olan çeşitli kütanöz aşırı duyarlılık reaksiyonlarına neden olabilmektedir. Morbiliform döküntüler, ürtiker, akut jeneralize ekzantematöz püstüloz (AGEP), Stevens-Johnson sendromu ve DRESS sendromu gibi klinik prezentasyonlar, farklı risk profilleri ve tedavi yaklaşımları gerektirir. Tedavideki temel hedef, nedensel ilacın doğru tanımlanarak kesilmesi ve hastanın güvenli bir alternatif tedaviye yönlendirilmesidir.
Antiepileptic drug use in children can lead to various cutaneous hypersensitivity reactions that are often challenging to diagnose and manage. Clinical presentations such as morbilliform rashes, urticaria, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, and DRESS syndrome require different risk assessments and treatment approaches. The primary goal in management is to accurately identify and discontinue the causative drug while transitioning the patient to a safe alternative treatment.
Referanslar
Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-37.
Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5(4):309-16.
Alvarado SA, Muñoz-Mendoza D, Bahna SL. High-risk drug rashes. Ann Allergy Asthma Immunol. 2018;121(5):552-60.
Mori F, Blanca-Lopez N, Caubet JC, Demoly P, Du Toit G, Gomes ER, et al. Delayed hypersensitivity to antiepileptic drugs in children. Pediatr Allergy Immunol. 2021;32(3):425-36.
Shin HT, Chang MW. Drug eruptions in children. Curr Probl Pediatr. 2001;31(7):207-34.
Dilek N, Özkol HU, Akbaş A, Kılınç F, Dilek AR, Saral Y, et al. Cutaneous drug reactions in children: a multicentric study. Postepy Dermatol Alergol. 2014;31(6):368-71.
Waldman R, Whitaker-Worth D, Grant-Kels JM. Cutaneous adverse drug reactions: Kids are not just little people. Clin Dermatol. 2017;35(6):566-82.
Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med. 2012;366(26):2492-501.
Heelan K, Shear NH. Cutaneous drug reactions in children: an update. Paediatr Drugs. 2013;15(6):493-503.
Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy. 2012;97:79-97.
Noguera-Morel L, Hernández-Martín Á, Torrelo A. Cutaneous drug reactions in the pediatric population. Pediatr Clin North Am. 2014;61(2):403-26.
Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-70.
Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55(4):496-506.
De shazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. Jama. 1997;278(22):1895-906.
Yawalkar N, Pichler WJ. Pathogenesis of drug-induced exanthema. Int Arch Allergy Immunol. 2001;124(1-3):336-38.
Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008;53(1):2-8.
Song JE, Sidbury R. An update on pediatric cutaneous drug eruptions. Clin Dermatol. 2014;32(4):516-23.
Hanson SG, Nigro JF. Pediatric dermatology. Med Clin North Am. 1998;82(6):1381-403
Deacock SJ. An approach to the patient with urticaria. Clin Exp Immunol. 2008;153(2):151-61.
Mortureux P, Léauté-Labrèze C, Legrain-Lifermann V, Lamireau T, Sarlangue J, Taïeb A. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol. 1998;134(3):319-23.
Jakubovic BD, Vecillas LL, Jimenez-Rodriguez TW, Sanchez-Sanchez S, Castells M. Drug hypersensitivity in the fast lane: What clinicians should know about phenotypes, endotypes, and biomarkers. Ann Allergy Asthma Immunol. 2020;124(6):566-72.
Muraro A, Lemanske RF, Jr., Castells M, Torres MJ, Khan D, Simon HU, et al. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy. 2017;72(7):1006-21.
Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Demographic and clinical profiles in patients with acute urticaria. Allergol Immunopathol (Madr). 2015;43(4):409-15.
Poon M, Reid C. Do steroids help children with acute urticaria? Arch Dis Child. 2004;89(1):85-86.
Arkachaisri T. Serum sickness and hepatitis B vaccine including review of the literature. J Med Assoc Thai. 2002;85 (Suppl 2):S607-12.
Frieling GW. Pediatric Drug Eruptions of the Skin. In: Hall JC, Hall BJ, editors. Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. London: Springer London; 2015. p. 431-44.
Guvenir H, Arikoglu T, Vezir E, Misirlioglu ED. Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. Curr Pharm Des. 2019;25(36):3840-54.
Yorulmaz A, Akın F, Sert A, Ağır MA, Yılmaz R, Arslan Ş. Demographic and clinical characteristics of patients with serum sickness-like reaction. Clin Rheumatol. 2018;37(5):1389-94.
Tolpinrud WL, Bunick CG, King BA. Serum sickness-like reaction: histopathology and case report. J Am Acad Dermatol. 2011;65(3):83-85.
Nguyen CV, Miller DD. Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern. J Cutan Pathol. 2017;44(2):177-82.
Tantawichien T, Benjavongkulchai M, Wilde H, Jaijaroensup W, Siakasem A, Chareonwai S, et al. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin Infect Dis. 1995;21(3):660-62.
Lundquist AL, Chari RS, Wood JH, Miller GG, Schaefer HM, Raiford DS, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl. 2007;13(5):647-50.
Hurwitz RM. Steroid acne. J Am Acad Dermatol. 1989;21(6):1179-81.
Chang DK, Shear NH. Cutaneous reactions to anticonvulsants. Semin Neurol. 1992;12(4):329-37.
Remmer HI, Falk WE. Successful treatment of lithium-induced acne. J Clin Psychiatry. 1986;47(1):48.
Feldmeyer L, Heidemeyer K, Yawalkar N. Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. Int J Mol Sci. 2016; 17(8):1214
Sidoroff A. Acute generalized exanthematous pustulosis. Chem Immunol Allergy. 2012;97:139-48.
Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, Duong TA, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol. 2013;169(6):1223-32.
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73(5):843-48.
Amaral L, Carneiro-Leão L, Cernadas JR. Acute Generalized Exanthematous Pustulosis Due to Clavulanic Acid. J Allergy Clin Immunol Pract. 2020;8(3):1083-84.
Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-96.
Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127(9):1333-38.
Chang SL, Huang YH, Yang CH, Hu S, Hong HS. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol. 2008;88(4):363-65.
Ofuji S, Yamamoto O. Acute generalized exanthematous pustulosis associated with a human parvovirus B19 infection. J Dermatol. 2007;34(2):121-23.
Lee D, Kang JN, Hwang SH, Lee YS, Kim H, Seo JK, et al. Acute generalized exanthematous pustulosis induced by parvovirus b19 infection. Ann Dermatol. 2014;26(3):399-400.
Lim CS, Lim SL. Acute generalized exanthematous pustulosis associated with asymptomatic Mycoplasma pneumoniae infection. Arch Dermatol. 2009;145(7):848-49.
Taguchi K, Oka M, Bito T, Nishigori C. Acute generalized exanthematous pustulosis induced by Mycoplasma pneumoniae infection. J Dermatol. 2016;43(1):113-14.
Haro-Gabaldón V, Sánchez-Sánchez-Vizcaino J, Ruiz-Avila P, Gutiérrez-Fernández J, Linares J, Naranjo-Sintes R. Acute generalized exanthematous pustulosis with cytomegalovirus infection. Int J Dermatol. 1996;35(10):735-37.
Feio AB, Apetato M, Costa MM, Sá J, Alcantâra J. Acute generalized exanthematous pustulosis due to Coxsackie B4 virus. Acta Med Port. 1997;10(6-7):487-91.
Manzano S, Guggisberg D, Hammann C, Laubscher B. Acute generalized exanthematous pustulosis: first case associated with a Chlamydia pneumoniae infection. Arch Pediatr. 2006;13(9):1230-32.
Klein N, Hartmann M, Helmbold P, Enk A. Acute generalized exanthematous pustulosis associated with recurrent urinary tract infections. Hautarzt. 2009;60(3):226-28.
Cannistraci C, Parola IL, Rigan OR, Bassetti F, Ortona E, Santucci B, et al. Acute generalized exanthematous pustulosis in cystic echinococcosis: immunological characterization. Br J Dermatol. 2003;148(6):1245-49.
Davidovici BB, Pavel D, Cagnano E, Rozenman D, Halevy S. Acute generalized exanthematous pustulosis following a spider bite: report of 3 cases. J Am Acad Dermatol. 2006;55(3):525-29.
Choi MJ, Kim HS, Park HJ, Park CJ, Lee JD, Lee JY, et al. Clinicopathologic manifestations of 36 korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature. Ann Dermatol. 2010;22(2):163-69.
Belhadjali H, Mandhouj S, Moussa A, Njim L, Amri M, Zakhama A, et al. Mercury-induced acute generalized exanthematous pustulosis misdiagnosed as a drug-related case. Contact Dermatitis. 2008;59(1):52-54.
Bonnetblanc JM, Combeau A, Dang PM. Hydroxychloroquine-puvatherapy photoinduced acute generalized exanthematous pustulosis. Ann Dermatol Venereol. 1995;122(9):604-605.
Meadows KP, Egan CA, Vanderhooft S. Acute generalized exanthematous pustulosis (AGEP), an uncommon condition in children: case report and review of the literature. Pediatr Dermatol. 2000;17(5):399-402.
Krishna S, Ortega-Loayza A, Malakouti N, Brinster N. A rapidly progressive and fatal case of atypical acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2014;71(3):89-90.
Schmid S, Kuechler PC, Britschgi M, Steiner UC, Yawalkar N, Limat A, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol. 2002;161(6):2079-86.
Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, et al. Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis. J Invest Dermatol. 2019;139(4):848-58.
Jakkidi M, Basmadjian C, Roy S. An illusion of septic shock: acute generalised exanthematous pustulosis with multiorgan dysfunction. BMJ Case Rep. 2017;2017.
McDonald KA, Pierscianowski TA. A Case of Amoxicillin-Induced Acute Generalized Exanthematous Pustulosis Presenting as Septic Shock. J Cutan Med Surg. 2017;21(4):351-55.
Mercogliano C, Khan M, Lin C, Mohanty E, Zimmerman R. AGEP overlap induced by hydroxychloroquine: a case report and literature review. J Community Hosp Intern Med Perspect. 2018;8(6):360-62.
Copaescu AM, Bouffard D, Masse MS. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review. Allergy Asthma Clin Immunol. 2020;16:19.
Azib S, Florin V, Fourrier F, Delaporte E, Staumont-Sallé D. Severe acute generalized exanthematous pustulosis with blistering mimicking toxic epidermal necrolysis, associated with a primary mumps infection. Clin Exp Dermatol. 2014;39(6):723-25.
Kley C, Murer C, Maul JT, Meier B, Anzengruber F, Navarini AA. Rapid Involution of Pustules during Topical Steroid Treatment of Acute Generalized Exanthematous Pustulosis. Case Rep Dermatol. 2017;9(1):135-39.
Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-19.
Thienvibul C, Vachiramon V, Chanprapaph K. Five-Year Retrospective Review of Acute Generalized Exanthematous Pustulosis. Dermatol Res Pract. 2015;2015
Nacaroğlu HT, Demet CJGP. Akut generalize ekzantematöz püstülozis. 2013;11(2):77-80.
Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555-62.
Diaz L, Ciurea AM. Cutaneous and systemic adverse reactions to antibiotics. Dermatol Ther. 2012;25(1):12-22.
Pai VV, Bhandari P, Kikkeri NN, Athanikar SB, Sori T. Fixed drug eruption to fluconazole: a case report and review of literature. Indian J Pharmacol. 2012;44(5):643-45.
Nakai N, Katoh N. Fixed drug eruption caused by fluconazole: a case report and mini-review of the literature. Allergol Int. 2013;62(1):139-41.
Khaled A, Kharfi M, Ben Hamida M, El Fekih N, El Aidli S, Zeglaoui F, et al. Cutaneous adverse drug reactions in children. A series of 90 cases. Tunis Med. 2012;90(1):45-50.
Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in north India. Pediatr Dermatol. 1995;12(2):178-83.
Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics. 2007;120(4):1082-96.
Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003;49(6):1003-07.
Nussinovitch M, Prais D, Ben-Amitai D, Amir J, Volovitz B. Fixed drug eruption in the genital area in 15 boys. Pediatr Dermatol. 2002;19(3):216-19.
Morelli JG, Tay YK, Rogers M, Halbert A, Krafchik B, Weston WL. Fixed drug eruptions in children. J Pediatr. 1999;134(3):365-67.
Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316-21.
Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002;161(4):1337-47.
Mizukawa Y, Shiohara T. Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses. Clin Exp Dermatol. 2010;35(5):493-97.
Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol. 2008;158(6):1230-38.
Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37(11):833-38.
Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6(3):181-88.
Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol. 1987;116(4):561-67.
Gupta R. Drugs causing fixed drug eruptions: confirmed by provocation tests. Indian J Dermatol Venereol Leprol. 2003;69(2):120-21.
Lee AY. Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis. 1998;38(5):258-60.
Arıcan Ö, Ürün M. Tenoksikam ile gelişen bir generalize (multifokal) büllöz fiks ilaç erüpsiyonu olgusu. Türk Geriatri Dergisi. 2008;11(4):200-03.
Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management. Am J Clin Dermatol. 2003;4(6):407-28.
Bhargava NC, Singh G. Fixed eruption due to two unrelated drugs: oxyphenbutazone and tetracycline. Int J Dermatol. 1981;20(6):435.
Zoghaib S, Kechichian E, Souaid K, Soutou B, Helou J, Tomb R. Triggers, clinical manifestations, and management of pediatric erythema multiforme: A systematic review. J Am Acad Dermatol. 2019;81(3):813-22.
Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889-902.
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Erythema Multiforme. Clin Rev Allergy Immunol. 2018;54(1):177-84.
Merrill ED, Stanford CW. Erythema Multiforme and Drug Reactions. In: Hall JC, Hall BJ, editors. Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. London: Springer London; 2015. p. 65-76.
Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am. 2013;57(4):583-96.
Bergmann MM, Caubet JC. Role of in vivo and in vitro Tests in the Diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to Drug. Curr Pharm Des. 2019;25(36):3872-80.
Roujeau JC. Re-evaluation of 'drug-induced' erythema multiforme in the medical literature. Br J Dermatol. 2016;175(3):650-51.
Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ. Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. Immunol Allergy Clin North Am. 2017;37(4):785-815.
Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6):28-30.
Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539-43.
Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease. Ocul Surf. 2016;14(1):2-19.
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.
Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):297-304.
Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811-817
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-85.
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173
Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94(4):419-36
Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990;23(6):1039-58.
Wong A, Malvestiti AA, Hafner Mde F. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. Rev Assoc Med Bras. 2016;62(5):468-73.
Goodman H. Nikolsky sign; page from notable contributors to the knowledge of dermatology. AMA Arch Derm Syphilol. 1953;68(3):334-35.
Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. Ocul Surf. 2016;14(2):168-88.
Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3):52-60.
Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group. JAMA Dermatol. 2017;153(6):587-92.
Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-68.
Techasatian L, Panombualert S, Uppala R, Jetsrisuparb C. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital. World J Pediatr. 2017;13(3):255-60.
Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013;98(12):998-1003.
White KD, Chung WH, Hung SI, Mallal S, Phillips EJ. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol. 2015;136(2):219-34
Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43(7):758-66.
Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1):155-61.
Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-50.
Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803-13
Nassif A, Bensussan A, Dorothée G, Mami-Chouaib F, Bachot N, Bagot M, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118(4):728-33.
Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;7(6):813-18.
De Prost N, Ingen-Housz-Oro S, Duong TA, Valeyrie-Allanore L, Legrand P, Wolkenstein P, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine. 2010;89(1):28-36.
Mayes T, Gottschlich M, Khoury J, Warner P, Kagan R. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract. 2008;23(5):547-50.
Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71(5):941-47.
Woolridge KF, Boler PL, Lee BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis. Cutis. 2018;101(1):15-21.
Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25(3):246-55.
Lin YT, Chang YC, Hui RC, Yang CH, Ho HC, Hung SI, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2013;27(3):356-64.
Roujeau JC, Albengres E, Moritz S, Piacentino A, Cuny M, Revuz J, et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol. 1985;78(1):22-24.
Polak ME, Belgi G, McGuire C, Pickard C, Healy E, Friedmann PS, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol. 2013;168(3):539-49.
Fu M, Gao Y, Pan Y, Li W, Liao W, Wang G, et al. Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain long-lived IFN-γ and sFasL memory response. PLoS One. 2012;7(9):45516.
Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2011;65(1):65-68.
Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014;70(3):539-48.
Kim GY, Anderson KR, Davis DMR, Hand JL, Tollefson MM. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature. J Am Acad Dermatol. 2020;83(5):1323-30.
Ardern-Jones MR, Mockenhaupt M. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2019;19(4):283-93.
Hiransuthikul A, Rattananupong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M, Ruxrungtham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand. Allergol Int. 2016;65(4):432-38.
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071-80.
Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics. 2001;108(2):485-92.
Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol. 2009;26(5):536-46.
Velasco MJ, McDermott J. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and hepatitis induced by phenytoin. Int J Dermatol. 2014;53(4):490-93.
Descamps V. Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. Br J Dermatol. 2015;172(4):858-59.
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609-11.
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693
Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, et al. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-53.
Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301-08.
Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? Am J Clin Dermatol. 2019;20(2):217-36.
Mayorga C, Ebo DG, Lang DM, Pichler WJ, Sabato V, Park MA, et al. Controversies in drug allergy: In vitro testing. J Allergy Clin Immunol. 2019;143(1):56-65.
Luque I, Leyva L, José Torres M, Rosal M, Mayorga C, Segura JM, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy. 2001;56(7):611-18.
Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-20.
Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf. 2009;32(5):391-408.
Mirakian R, Ewan PW, Durham SR, Youlten LJ, Dugué P, Friedmann PS, et al. BSACI guidelines for the management of drug allergy. Clin Exp Allergy. 2009;39(1):43-61.
Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am. 2009;29(3):517-35.
Ting TY. Anticonvulsant hypersensitivity syndrome: identification and management. Curr Treat Options Neurol. 2007;9(4):243-48.
Gelincik A, Cavkaytar O, Kuyucu S. An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions. Curr Pharm Des. 2019;25(36):3881-901.
Descamps V, Ranger-Rogez S. DRESS syndrome. Joint Bone Spine. 2014;81(1):15-21.
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol. 2013;68(5):709
Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol. 2005;64(2):155-58.
Alexander T, Iglesia E, Park Y, Duncan D, Peden D, Sheikh S, et al. Severe DRESS syndrome managed with therapeutic plasma exchange. Pediatrics. 2013;131(3):945-49.
Singer EM, Wanat KA, Rosenbach MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol. 2013;149(4):494-95.
Mısırlıoğlu ED, Damadoğlu E, Cavkaytar Ö. Ağır İlaç Aşırı Duyarlılık Reaksiyonları: Türkiye Ulusal Rehberi 2020. Mısırlıoğlu ED, Damadoğlu E, Cavkaytar Ö, editors. Ankara.2020
